Westpac sells NZ life arm to Fidelity Life for NZ$400m
July 6 2021 by Andrew Tjaardstra
-
‘No guarantee’ Allianz-Income deal will proceed, discussions ongoing
- November 15
Allianz and Income Insurance said they are still having discussions on amendments to the proposed acquisition deal.
-
Emerging capital standards to increase Korea, HK and Taiwan insurance consolidation: Fitch Ratings
- November 15
Regulators in the Asia Pacific region are upgrading existing solvency frameworks with a growing emphasis on aligning with ICS, IFRS 17 and other global regimes.
-
Envest acquires majority stake in Bendigo Insurance Brokers
- November 14
The merger will add the broker to the network of Aviso Group and will bring the combined GWP up to US$616.4bn with the addition of the broker's US$13.3mn of gross written premium.
-
Singapore blocked Income-Allianz deal over US$1.4bn ‘capital extraction’ plan
- November 14
The proposed plan is “very different in both its nature and quantum” and “does not align with the representations NTUC Income made” to the government, MAS chairman said.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
